IRAK4-IN-22

IRAK4-IN-22 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 3 nM) and TAK1 (IC50: 17 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.10 μM. IRAK4-IN-21 can be used to study autoimmune diseases, such as plaque psoriasis and psoriatic arthritis.

KTX-951, a PROTAC designed for IRAK4 degradation (DC 50 =18 nM), exhibits an oral bioavailability (F%) of 22% in a rat model at a dosage of 10 mg kg. Additionally, KTX-951 demonstrates promising anticancer potential [1].

IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor with an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, making it a valuable agent for DLBCL research [1].